To view this video, please enable marketing cookies from Cookie Preferences in the footer.
Statins (HMG-CoA Reductase Inhibitors) are the foundation of LDL lowering and ASCVD prevention. In this lecture from This is Why, Dr. Busti will make statin pharmacology easy to understand, but also clinically relevant in the proper context of the evidence. The use of HMG CoA reductase inhibitors: atorvastatin, rosuvastatin, simvastatin, pitavastatin, and pravastatin are drugs in this drug class that Dr. Busti will review.
You’ll learn how to:
- MOA: How HMG-CoA reductase inhibitors reduce hepatic cholesterol synthesis and increase LDL clearance
- Clinical uses: Hyperlipidemia treatment, primary prevention, and secondary prevention for ASCVD
- High-yield statins: Atorvastatin, rosuvastatin, simvastatin, pravastatin (and how to think about intensity)
- Adverse effects: Statin myopathy, muscle pain/weakness, and rare rhabdomyolysis
- Key interactions: CYP3A4 interactions (especially with certain statins) and what to watch for clinically
- Pearls for exams: How to connect lipid lowering drugs to patient cases and test questions
The goal = make medical education easy and clinically relevant.
Chapter Table of Contents
00:00:00 Statins Overview: LDL-Lowering Cornerstone Therapy
00:01:57 Statin Agents: High- vs Moderate-Intensity Options
00:03:22 Indications: Primary & Secondary ASCVD Prevention
00:04:36 Net Clinical Benefit: Mortality & CV Event Reduction
00:05:29 LDL-Lowering Potency: Expected % Reductions by Statin
00:06:16 Pleiotropic Effects: Plaque Stabilization & Endothelial Function
00:07:36 Core Mechanism: HMG-CoA Reductase Inhibition → ↑LDL Receptors
00:09:30 Lipid Effects Beyond LDL: TG ↓, HDL ↑, ApoB ↓
00:11:34 Cholesterol Biosynthesis Pathway: Where Statins Act
00:16:29 PK/PD Differences Among Statins (Half-Life, Lipophilicity)
00:18:25 Timing of Dosing: Short- vs Long-Acting Statins
00:21:32 Drug Metabolism & Transporters: CYP, UGT, P-gp, BCRP
00:26:06 Major Interactions: Gemfibrozil, Amiodarone, Protease Inhibitors
00:35:10 Safety: Hepatotoxicity & Muscle Injury Are Dose-Dependent
00:57:20 Landmark Trials: Evidence for Primary & Secondary Prevention
If this helped you, please like, subscribe to our YouTube Channel, and share it with a classmate or colleague. That will help this new channel continue producing free, high-yield medical education content.
Don’t forget to turn on notifications on YouTube so you don’t miss upcoming lectures in pharmacology, medical rounds, and more!
#statins #hmgcoareductaseinhibitors #ldllowering #lipidloweringdrugs #busti
Disclaimer:
This content is for educational purposes only and is not medical advice. It does not replace individualized evaluation, diagnosis, or treatment. Always seek the advice of a qualified health provider with questions about a medical condition and never delay care because of educational content.
More than just access—it’s where understanding deepens.
Create a free account or log in to gain access to this content!
Related Topics
